News

May 20, 2024

Fast Track Designation follows announcement in January 2024 that the U.S. Food and Drug Administration (FDA) granted a “Study May Proceed” letter for APRINOIA’s planned Phase 3 study of APN-1607 (florzolotau (18F)) in the U.S.,U.K., Europe and Asia May 20, 2024 08:00 ET CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“APRINOIA” or the “Company”), a clinical-stage...

January 3, 2024

Cambridge, MA, January 3, 2024 -- APRINOIA Therapeutics Inc. (“APRINOIA” or the “Company”) is pleased to announce that on December 8, 2023, the United States Food and Drug Administration (“FDA”) has issued a “Study May Proceed” letter for APRINOIA’s newly filed investigational new drug application for the clinical investigation of a Phase 3, open-label, multicenter, prospective study of the dia...

September 11, 2023

Investment Supports APRINOIA’s Effort to Bring Precision Medicine to Neuroscience, Advancing APRINOIA’s Diagnostic and Therapeutic Pipelines. Funding Supports APRINOIA’s Goal to Bring a Central Nervous System (CNS) Protein Degrader Candidate to Investigational New Drug (IND)-Enabling Study. Proceeds also Intended to Advance APRINOIA’s Late-Stage Tau Positron Emission Tomography (PET) ...

August 28, 2023

Dr. Shearman, a pharma and biotech industry executive with an extensive track record of achievements in drug discovery and development, will lead the strategy and execution of the company's clinical therapeutic and diagnostic programs August 28, 2023 11:00 ET APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision d...

August 23, 2023

CAMBRIDGE, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for the treatment of neurodegenerative diseases such as Alzheimer's Disease (“AD”) and Progressive Supranuclear Palsy (“PSP”), announced a mutual termination of its previously announced business combinat...

January 18, 2023

ROSS SPAC will issue $280 million of stock for APRINOIA Therapeutics Precision Neurology Company Focused on Developing a Pipeline of Highly Specific Central Nervous System (“CNS”) Diagnostics and Therapeutics, including CNS Protein Degraders Anticipated Proceeds From Transaction Expected to Finance Several Key Therapeutic and Diagnostic Programs to Data Announcements Business Combination is ...

April 11, 2022

BOSTON, April 11, 2022 -- APRINOIA Therapeutics announces today that the U.S. Food and Drug Administration (FDA) has granted a may proceed authorization for its novel therapeutic anti-tau monoclonal antibody, APNmAb005, allowing the company to test and evaluate its safety in healthy subjects in a phase 1 single ascending dose study. APNmAb005 is a unique antibody that recognizes a ...

December 28, 2021

APRINOIA Therapeutics has completed Series C financing with a total amount of $40 million USD in 2021. The financing was led by Yantai Dongcheng Pharmaceutical Group and syndicated by current shareholders KTB Network, IMM, and TaiAn Technologies and several new investors, including Harvest Capital, a fund established by the Management Committee of Suzhou Industrial Park (SIP). The new fun...

December 30, 2020

TAIPEI, Taiwan, Dec. 30, 2020 /PRNewswire/ --  Insilico Medicine is pleased to announce that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico's novel generative artificial intelligence (AI) technology to accelerate the discovery of next generation compounds targeting abnormal proteins in brain associated with neurodegenerative ...

December 16, 2020

APRINOIA Therapeutics Inc. today announced that they had executed a worldwide non-exclusive licensing agreement for Biogen Inc. (Nasdaq: BIIB) to access APRINOIA’s positron emission tomography (PET) imaging tracer, 18F-APN-1607, for neurodegenerative diseases. This is an extension of a collaboration between APRINOIA and Biogen to discover novel PET imaging tracers for visualization and quantifi...